SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced the closing of an underwritten public offering of 8,700,000 shares of its common stock, offered at a price of $5.75 per share to the public. The gross proceeds to the Company from this offering were approximately $50 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares in the offering were sold by the Company.

Visit link:
Catalyst Biosciences Announces Closing of Public Offering of Common Stock